

*sub
CS X*
B
B

SEQ ID NO: 1 or an analyte thereof related to said ~~disease state~~ *myocardial infarction or renal failure*; and means for determining binding between said biochemical material and said biomolecule; whereby at least one analysis to determine a presence of a marker, analyte thereof, or a biochemical material specific thereto, is carried out on a sample.

B 4

25. The kit of claim 18, wherein said marker includes the sequence identified as SEQ ID NO: 1 or at least one analyte thereof and said biochemical material is at least one monoclonal antibody specific therefore.

B

29. Polyclonal antibodies produced against the marker having a sequence identified as SEQ ID NO: 1 in at least one animal host.

B

30. An antibody that specifically binds a biopolymer including the marker sequence identified as SEQ ID NO: 1 or at least one analyte thereof.

*sub
CS X*
B 6

33. A process for identifying therapeutic avenues related to a ~~disease state~~ *myocardial infarction or renal failure* comprising: conducting an analysis as provided by the kit of claim 18; and interacting with a biopolymer including the sequence identified as SEQ ID NO: 1 or at least one analyte thereof; whereby therapeutic avenues are developed.

*sub
B 6*

34. The process for identifying therapeutic avenues related to a ~~disease state in~~ *myocardial infarction or renal failure*